H. Angell

P. Jänne, L. Sequist, J. Wolf, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

D. Gibbons, M. Roudier, Dong-Wan Kim, 2020, British Journal of Cancer.

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

J. Barrett, S. Park, D. Hodgson, 2018, Oncoimmunology.

Correlation between density of CD8 T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy Running title: CD8 cell density correlates with mutations in MSI-CRCs

Aurélie, B. Mlecnik, J. Latouche, 2015 .

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Y. Drew, R. Plummer, P. Roxburgh, 2022, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

S. Domchek, Sang-We Kim, F. Barlesi, 2017 .

The immune landscape of human tumors

J. Galon, B. Mlecnik, G. Bindea, 2014, Oncoimmunology.

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.

S. Domchek, Sang-We Kim, M. D. de Jonge, 2023, Lung cancer.

Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC)

J. Barrett, D. Hodgson, E. Kilgour, 2016 .

Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates

Knowles, J. Barrett, E. Harrington, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

F. Marincola, J. Galon, D. Bedognetti, 2013, Immunity.

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

J. Galon, M. Secrier, H. Angell, 2023, Cancer research communications.

39 A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC

J. Blando, S. Sridhar, A. Spitzmüller, 2021, Journal for ImmunoTherapy of Cancer.

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.

D. Gibbons, M. Roudier, M. Marotti, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Z. Trajanoski, M. Speicher, P. Laurent-Puig, 2016, Immunity.

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, S. Im, 2019, Poster Discussion Abstracts.